Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanfacine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanfacine SCHEMBL15603414 | 0.98 | ADRA2A (1.00) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| Guanfacine SCHEMBL1133622 | 0.96 | ADRA2A (0.93) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL11391966 | 0.83 | KMT2A (0.71) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| Guanfacine SCHEMBL28172481 | 0.82 | KMT2A (0.68) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL31231111 | 0.81 | ADRA2A (0.68) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL439567 | 0.80 | KMT2A (0.67) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL439566 | 0.80 | KMT2A (0.67) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL10918195 | 0.80 | ADRA2A (0.67) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL10921192 | 0.80 | ADRA2A (0.66) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL10308390 | 0.79 | KMT2A (0.65) | ADRA2AKMT2AMEN1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14003 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934622-B1 | DELAYED RELEASE METHYLPHENIDATE COMPOSITIONS | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260115163-A1 | NOVEL TREATMENTS | 3Z EHF (IS) | 2026-04-30 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4719368-A1 | INJECTABLE GUANFACINE FORMULATIONS AND METHODS | Cumberland Pharmaceuticals Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4712996-A1 | HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER | THE HEALTHY AGING COMPANY (FR) | 2026-03-25 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| CN-121570440-A | High-water permeability and high-adhesion pressure-sensitive adhesive patch matrix and preparation method and application thereof | 沈阳药科大学 | 2026-02-27 | — | — | CN | claimed |
| US-4783456-A | A-ADRENERGIC BLOCKING AGENTS | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 1988-11-08 | — | — | US | claimed |
| US-4764382-A | EMULSION POLYMERIZED POLYVINYL CHLORIDE, GELS | HERCON LABORATORIES CORPORATION (US) | 1988-08-16 | — | — | US | claimed |
| US-4758434-A | Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant | HERCON LABORATORIES CORPORATION (US) | 1988-07-19 | — | — | US | claimed |
| EP-0268912-A2 | Pharmaceutical composition comprising alpha-2I-selective adrenergic receptor agonists and the use thereof in memory enhancement | YALE UNIVERSITY (US) | 1988-06-01 | — | — | EP | claimed |
| EP-0251425-A1 | Article for administration of pharmacologically-active substances | HERCON LABORATORIES CORPORATION (US) | 1988-01-07 | — | — | EP | claimed |
| EP-0184910-A2 | Device for controlled release drug delivery | HERCON LABORATORIES CORPORATION (US) | 1986-06-18 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| EP-0164320-A1 | Pharmaceutical preparations for spinal analgesia containing guanfacine, and method for their preparation | Astra Läkemedel Aktiebolag (SE) | 1985-12-11 | — | — | EP | claimed |
| US-4404226-A | NEUROLEPTIC AGENTS | SANDOZ LTD. (CH) | 1983-09-13 | — | — | US | claimed |
| US-4380550-A | Guanfacine in treating opiate addiction | SANDOZ LTD. (CH) | 1983-04-19 | — | — | US | claimed |